BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 16210037)

  • 1. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
    Falanga A; Marchetti M; Barbui T; Smith CW
    Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.
    Falanga A; Barbui T; Rickles FR
    Semin Thromb Hemost; 2008 Mar; 34(2):204-10. PubMed ID: 18645927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
    Elliott MA; Tefferi A
    Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
    Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
    Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
    Petrides PE; Siegel F
    Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
    Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
    Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
    Falanga A; Marchetti M; Evangelista V; Vignoli A; Licini M; Balicco M; Manarini S; Finazzi G; Cerletti C; Barbui T
    Blood; 2000 Dec; 96(13):4261-6. PubMed ID: 11110700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.
    Murphy S
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):9-13. PubMed ID: 9930551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis.
    Rusak T; Ciborowski M; Uchimiak-Owieczko A; Piszcz J; Radziwon P; Tomasiak M
    Platelets; 2012; 23(6):455-62. PubMed ID: 22098131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC; Gómez M
    Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.